antimicrobial stewardship

antimicrobial stewardship is a coordinated effort to promote the appropriate use of antimicrobial agents. Its primary goals are to improve patient outcomes, ensure cost-effective therapy, and reduce the adverse ecological consequences of antimicrobial use, most notably the development of antimicrobial resistance. These programs are essential components of modern healthcare, operating within hospitals, long-term care facilities, and outpatient settings to preserve the efficacy of existing drugs.

Definition and scope

The formal concept emerged in response to the escalating global crisis of antimicrobial resistance, which threatens the effectiveness of vital drugs like penicillin and vancomycin. Core definitions, such as those from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America, emphasize a systematic approach. The scope extends beyond simply reducing use to optimizing drug selection, dosage, route of administration, and duration of therapy for bacterial, viral, fungal, and parasitic infections. It is inherently interdisciplinary, involving collaboration among infectious disease physicians, clinical pharmacists, microbiologists, and infection control practitioners.

Core strategies and interventions

Stewardship employs a blend of restrictive and persuasive strategies. Restrictive or "front-end" interventions include formulary restriction and prior authorization, often managed through an antibiotic approval system. Persuasive or "back-end" strategies encompass prospective audit and feedback, where experts like those from the Centers for Disease Control and Prevention recommend review programs. Key evidence-based interventions are de-escalation of therapy based on culture results, automatic changes from intravenous to oral therapy, and adherence to institution-specific clinical guidelines such as those for community-acquired pneumonia or urinary tract infection. The use of rapid diagnostic tests from companies like BioMérieux or Cepheid facilitates quicker, more targeted therapy.

Implementation and programs

Successful implementation requires dedicated personnel, institutional support, and a formalized structure. Many programs are led by an Antimicrobial Stewardship Program team, a model promoted by regulatory bodies like The Joint Commission. Core members often include an infectious diseases physician and a pharmacist, as outlined in guidelines from the World Health Organization. Implementation frameworks, such as the "Core Elements" from the Centers for Disease Control and Prevention, provide a blueprint for hospitals and nursing homes. National initiatives, including the United Kingdom's English Surveillance Programme for Antimicrobial Utilisation and Resistance and the European Union's European Centre for Disease Prevention and Control, coordinate broader efforts.

Measurement and outcomes

Measuring impact is critical and involves tracking process and outcome metrics. Process measures assess compliance with interventions, such as rates of de-escalation or appropriate duration of antibiotic therapy. Outcome measures evaluate the effect on patient health and microbial ecology, including rates of Clostridioides difficile infection, antimicrobial resistance patterns in pathogens like methicillin-resistant Staphylococcus aureus and carbapenem-resistant Enterobacteriaceae, and overall antimicrobial consumption measured by metrics like defined daily dose. Benchmarking data is often collected through surveillance networks like the National Healthcare Safety Network.

Challenges and future directions

Significant challenges persist, including diagnostic uncertainty, lack of rapid diagnostics in resource-limited settings, and prescriber behavior influenced by defensive medicine. The World Health Assembly has recognized antimicrobial resistance as a major threat, calling for global action. Future directions focus on technological innovation, such as advanced molecular diagnostics and the application of artificial intelligence to guide therapy. Expanding stewardship principles to veterinary medicine and agriculture, as guided by the World Organisation for Animal Health, is crucial for a One Health approach. The development of novel antibiotics through initiatives like the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator must be coupled with sustainable stewardship to protect their utility.

Category:Infectious diseases Category:Public health Category:Medical hygiene